Sonnet BioTherapeutics 2024 Corporate Presentation

Sonnet BioTherapeutics is a clinical-stage biopharmaceutical company developing targeted immuno-oncology drugs utilizing a validated albumin-binding approach to convert 'cold' tumors to 'hot' for enhanced tumor penetration and immune activation. The company's modular technology platform targets albumin-binding receptors (FcRn, GP60, SPARC) with applications in solid tumors and benefits from material supply agreements with Roche and pipeline evaluation partnerships with J&J.